Education
About Us
Working with TipRanks
Follow Us
Innoviva Inc (INVA)
NASDAQ:INVA
INVA Stock Chart & Stats
$21.80
-$0.05(-0.29%)
At close: 4:00 PM EST
$21.80
-$0.05(-0.29%)
Day’s Range― - ―
52-Week Range$16.52 - $22.76
Previous CloseN/A
Volume64.08K
Average Volume (3M)643.60K
Market Cap
$1.63B
Enterprise Value$1.24B
Total Cash (Recent Filing)$533.10M
Total Debt (Recent Filing)$323.23M
Price to Earnings (P/E)15.5
Beta0.19
Next Earnings
Mar 04, 2026EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.08
Shares Outstanding74,769,060
10 Day Avg. Volume780,006
30 Day Avg. Volume643,603
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)1.57
Price to Sales (P/S)3.03
P/FCF Ratio5.78
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit3.68
Enterprise Value/Ebitda6.16
Forecast
1Y Price Target
$38.50Price Target Upside76.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ValidationPositive Phase 3 results published in The Lancet and demonstration of non-inferiority to standard therapy strengthen clinical credibility and may encourage physician adoption of zoliflodacin.
Regulatory ApprovalFDA approval of NUZOLVENCE (zoliflodacin) for oral suspension creates a new single-dose oral treatment option for uncomplicated urogenital gonorrhea, supporting potential revenue growth for Innoviva.
Regulatory IncentivesQualified Infectious Disease Product (QIDP) designation provides priority review and extended market exclusivity that can help protect NUZOLVENCE sales from early generic competition.
Bears Say
Commercial Penetration RiskGlaxoSmithKline's larger commercial infrastructure could accelerate uptake of its competing therapy, challenging Innoviva's ability to secure target prescribers with a proprietary sales effort.
Competitive LaunchFDA approval and planned launch of gepotidacin by GlaxoSmithKline introduces a direct, well-funded rival that could reduce market share available to NUZOLVENCE.
Pricing PressurePresence of multiple oral treatment options for gonorrhea may create pricing pressure and limit revenue per treatment compared with a single-product market.
Innoviva News
INVA FAQ
What was Innoviva Inc’s price range in the past 12 months?
Innoviva Inc lowest stock price was $16.52 and its highest was $22.76 in the past 12 months.
What is Innoviva Inc’s market cap?
Innoviva Inc’s market cap is $1.63B.
When is Innoviva Inc’s upcoming earnings report date?
Innoviva Inc’s upcoming earnings report date is Mar 04, 2026 which is in 21 days.
How were Innoviva Inc’s earnings last quarter?
Innoviva Inc released its earnings results on Nov 05, 2025. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.62.
Is Innoviva Inc overvalued?
According to Wall Street analysts Innoviva Inc’s price is currently Undervalued.
Does Innoviva Inc pay dividends?
Innoviva Inc pays a Quarterly dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Innoviva Inc dividends here
What is Innoviva Inc’s EPS estimate?
Innoviva Inc’s EPS estimate is 0.6.
How many shares outstanding does Innoviva Inc have?
Innoviva Inc has 74,769,060 shares outstanding.
What happened to Innoviva Inc’s price movement after its last earnings report?
Innoviva Inc reported an EPS of $1.08 in its last earnings report, beating expectations of $0.46. Following the earnings report the stock price went up 12.891%.
Which hedge fund is a major shareholder of Innoviva Inc?
Currently, no hedge funds are holding shares in INVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innoviva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.50 (76.61% Upside)
$38.50 (76.61% Upside)
Blogger Sentiment
Bullish
INVA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 312.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.38%
12-Months-Change
Fundamentals
Return on Equity
15.17%
Trailing 12-Months
Asset Growth
16.04%
Trailing 12-Months
Company Description
Innoviva Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
INVA Stock 12 Month Forecast
Average Price Target
$38.50
▲(76.61% Upside)
Technical Analysis
Ownership Overview
8.51% Insiders
21.16% Mutual Funds
0.91% Other Institutional Investors
40.41% Public Companies and
Individual Investors